N/A
Completed N=200
Regent China Post-Market Clinical Follow-up Study
Source: ClinicalTrials.gov NCT05330468 ↗Enrolled (actual)
200
Serious AEs
33.5%
Results posted
Oct 2025
Primary outcomePrimary: Primary Safety Endpoint: The Freedom From Valve-related Mortality — 98.4 percentage of participants
Summary
Regent China Post-Market Clinical Follow-Up (RC-PMCF): this clinical study is to confirm the safety and performance of Abbott's Regent MHV for replacement of native or prosthetic aortic valves in a Chinese population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary Safety Endpoint: The Freedom From Valve-related Mortality |
98.4 | — |
| PRIMARY Primary Performance Endpoint: The Freedom From Valve-related Reoperation |
99.5 | — |
Eligibility Criteria
Inclusion Criteria
- Patient is eligible to be implanted with Regent to replace a native or prosthetic aortic valve per Regent's IFU.
- Subject will be >18 years of age at time of being consented.
- Subject, provides written informed consent prior to any clinical investigation-specific procedure.
Exclusion Criteria
- Subject is unable to tolerate anticoagulation therapy.
- Subject has active endocarditis.
- Subject is currently participating in another clinical investigation which may interfere with the effectiveness of anticoagulation therapy.
- Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. Women of child-bearing potential must have a documented negative pregnancy test within one week prior to enrollment.
- Subject has anomalous anatomy or medical, surgical, psychological or social history or conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results.
- Subject is unable to read or write or has a mental illness or disability that impairs their ability to provide written informed consent.
- Subject's life expectancy is less than 1 year in the opinion of the Investigator.
Data sourced from ClinicalTrials.gov (NCT05330468). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.